Target intelligence / Profile preview

Polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4)

Target
GalNAc-T4
Molecular classification
Enzyme, Glycosyltransferase, Type II transmembrane protein
01

Overview

Polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) is an enzyme in the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family that initiates mucin-type O-linked glycosylation in the Golgi apparatus by transferring GalNAc to serine and threonine residues of substrate proteins. The enzyme is a type II transmembrane protein consisting of an N-terminal cytoplasmic region, a transmembrane anchor, a stem region, a catalytic GT-A fold domain, and a C-terminal ricin/lectin-like domain. GalNAc-T4 exhibits both short-range and long-range substrate preferences: it preferentially glycosylates serine/threonine residues just C-terminal to a pre-existing N-terminal glycosylated site on the substrate, a specificity determined by its catalytic and lectin domains connected via a flexible linker. The structure and substrate specificity of GalNAc-T4 distinguish it from related transferase isoforms, making it important both for the initial steps of mucin-type O-glycosylation and for the consequent structural and functional diversity of glycoproteins in health and disease. No direct therapeutic agents targeting GalNAc-T4 are approved or in late-stage clinical development, but dysregulation of GalNAc-T4 and related enzymes is widely implicated in cancer and other pathological states.

Other names
GALNT4UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4Polypeptide GalNAc-transferase 4GalNAc-T4
02

Mechanism of action

Catalyzes the transfer of an N-acetylgalactosamine molecule from UDP-GalNAc to the hydroxyl group of a serine or threonine residue in polypeptides. Prefers glycopeptide substrates with an N-terminally glycosylated threonine, recognizes polypeptide sequence and prior glycosylation state through distinct catalytic and lectin domains.

03

Biological functions

O-linked glycosylation (catalyzes the transfer of N-acetylgalactosamine (GalNAc) to serine and threonine residues in target proteins)Protein post-translational modificationModulation of mucin-type O-glycan biosynthesis
04

Disease associations

Cancer (as altered mucin-type glycosylation is strongly implicated in tumor progression and metastasis)Other (altered expression or mutations in GalNAc-Ts, including GalNAc-T4, have been linked to disease states such as developmental disorders and potentially other pathologies, but specific clinical correlations for GalNAc-T4 remain less defined)
05

Safety considerations

No specific drug- or therapy-associated safety concerns known for GalNAc-T4, but general glycosyltransferase inhibition could interfere with protein function and secretion, increasing risk of off-target physiological disruption.
06

Interacting drugs

None directly documented as of current literature and data; no small molecule inhibitors or therapeutic agents currently known to target GalNAc-T4 specifically
07

Biomarkers

No established clinical biomarkers for GalNAc-T4 activity or expression, but changes in mucin-type O-glycosylation (affected by GalNAc-T4 activity) may be exploitable as research biomarkers in certain carcinomas.

Beyond the preview

Go deeper on Polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call